Search - tctmd.com

Displaying 261 - 280 of 702

Sort: Relevancy | Date

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

News Conference News EuroPCR 2019

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Michael O'Riordan

May 02, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Daily News

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Michael O'Riordan

April 11, 2019

News Daily News

Baseline Anemia Ups Physician-Guided DAPT Discontinuation Rates After PCI

Yael L. Maxwell

April 10, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Yael L. Maxwell

March 07, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Baseline Anemia Ups Physician-Guided DAPT Discontinuation Rates After PCI

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content